Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC294640 in Advanced Hepatocellular Carcinoma Progressed on Sorafenib
NCT02939807Phase 2Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Opaganib in hepatocellular carcinoma (HCC), sponsored by Medical University of South Carolina. Primary endpoint: Objective Response Rate at 16 weeks. Planned start Sep 2019; status: withdrawn.
02
Drugs
Opaganib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02939807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939807.